AK137
/ Akesobio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 15, 2024
AK137-101: AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors
(clinicaltrials.gov)
- P1 | N=87 | Not yet recruiting | Sponsor: Akeso
Metastases • New P1 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1